What's Happening?
ISOThrive Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 study of MHS-1031, a treatment for patients with Non-Erosive Reflux Disease (NERD) who do not respond adequately to proton pump inhibitors (PPIs).
The study, presented at Digestive Disease Week 2026, demonstrated statistically significant reductions in heartburn incidence, severity, and regurgitation. MHS-1031 is designed to modulate the esophageal microbiome, offering a novel approach beyond traditional acid suppression therapies. The study is being conducted under an Investigational New Drug (IND) application with the FDA, involving researchers from Vanderbilt University, University of Virginia, and Eastern Virginia Medical School.
Why It's Important?
The development of MHS-1031 is significant as it addresses a substantial unmet need in the treatment of NERD, which affects approximately 70% of the GERD population in the U.S., estimated at 45 million adults. Current treatments, including PPIs and potassium-competitive acid blockers (PCABs), often fail to fully control symptoms in NERD patients due to the complex pathophysiology of the disease. MHS-1031's ability to improve symptom severity and regurgitation could represent a major advancement in treatment options, potentially benefiting millions of patients who experience persistent symptoms despite existing therapies.
What's Next?
ISOThrive's promising Phase 2 results may lead to further clinical trials to confirm the efficacy and safety of MHS-1031. If successful, this could pave the way for regulatory approval and commercialization, providing a new treatment option for NERD patients. The company may also explore partnerships or collaborations to support the development and distribution of MHS-1031. Stakeholders, including healthcare providers and patients, will likely monitor these developments closely, given the potential impact on treatment paradigms for gastrointestinal diseases.
